Strength in numbers: The quest for asthma genes - 05/08/19
Key words : Genetic risk factors, childhood-onset asthma, adult-onset asthma
Le texte complet de cet article est disponible en PDF.
Disclosure of potential conflict of interest: D. Vercelli is currently supported by research grants from VIFOR/OM-Pharma, the National Institute of Allergy and Infectious Diseases, and the National Heart, Lung, and Blood Institute and previously received research support from Johnson & Johnson. E. R. Bleecker has undertaken clinical trials through his employers, Wake Forest School of Medicine and the University of Arizona, for AstraZeneca, MedImmune, Boehringer Ingelheim, Genentech, Novartis, Regeneron, and Sanofi Genzyme and has served as a paid consultant for ALK-Abelló, AstraZeneca, GlaxoSmithKline, MedImmune, Novartis, Regeneron, Sanofi Genzyme, and TEVA. |
Vol 144 - N° 2
P. 413-415 - août 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?